Nephrology | Rheumatology

Roche Service Portal

We combine our long-standing expertise in immunology and our innovative strength to make a meaningful difference for patients with kidney disease. The Roche Service Portal is designed to help you find relevant information quickly or connect with us directly.

 

For inquiries, please reach out to us at serviceportal.nephrology@roche.com.
How can we help you today?

-> Jump to news or studies
Products Rheumatology
Explore our therapies for nephrology and rheumatology
Discover our therapies
Nephrology
Register as a customer in our online shop and order products directly from Roche.
Place orders
Gazyvaro Actemra
Find all the materials you need for your practice and your patients
Nephrology
Can't find what you are looking for or need further information? Get support.
News
Gazyva Gazyvaro
Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF), is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN).
Read more
Gazyvaro Nephrology
Gazyvaro® (obinutuzumab) is approved in Switzerland for the indication of lupus nephritis, on the Swiss specialties list and reimbursed accordingly.
Read more
Gazyvaro Lupus Nephritis
At a glance: Obinutuzumab achieved higher rates of histologic remission compared to placebo (adjusted difference, 30.75%), even among clinical CRR non-responders.
Browse the study

Pressed for time? View our studies in a bite-sized format.

Explore studies
Your Roche Team
Dr. Judit Axmann

Senior Medical Science Manager
Contact
Dr. Meret Lauterburg

Medical Science Manager
Contact
Rebekkah Amberg

Ecosystems Manager
Contact
Dr. Alessandro M. Strebel

Integrated Strategy Lead
Contact
Dr. Pia-Amata Leimbacher

Patient Journey Partner Lead
Contact

All references can be found in the respective news article.

Full professional information for the products mentioned can be found on the respective product page or at www.swissmedicinfo-pro.ch.
Roche Pharma (Switzerland) Ltd assumes no responsibility for the accuracy, legality, or content of the external site or any subsequent links. Please note that by leaving the Swiss HCP portal, you accept that information on external websites may not align with the product's approved use in Switzerland. The Swiss prescribing information remains the primary source of information for Swiss HCPs. Should you have any questions regarding the content of the external site, please contact them directly.
Restricted

Bookmarking is available only for logged-in users.

Sign up Log in